Pazopanib as third-line therapy for metastatic renal cell carcinoma: Clinical efficacy and temporal analysis of cytokine profile

被引：0
|
作者：
Pal, Sumanta K. [1 ]
Hossain, Dewan Md Sakib [1 ]
Zhang, Qifang [1 ]
Gao, Chan [1 ]
Jones, Jeremy O. [1 ]
Frankel, Paul H. [1 ]
Figlin, Robert A. [2 ]
Kortylewski, Marcin [1 ]
机构：
[1] City Hope Natl Med Ctr, Ctr Comprehens Canc, Duarte, CA USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT334
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of Pazopanib in the treatment of metastatic renal cell carcinoma
    Marmesat Rodas, B.
    Marquez Fernandez, E.
    Quesada Sanz, M. P.
    Guerra Estevez, D.
    Villanueva Jimenez, P.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 572 - 572
  • [22] Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
    Hutson, Thomas E.
    Davis, Ian D.
    Machiels, Jean-Pascal H.
    De Souza, Paul L.
    Rottey, Sylvie
    Hong, Bao-fa
    Epstein, Richard J.
    Baker, Katherine L.
    McCann, Lauren
    Crofts, Theresa
    Pandite, Lini
    Figlin, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 475 - 480
  • [23] Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Heng, Daniel Yick Chin
    Stukalin, Igor
    Wells, Connor
    Donskov, Frede
    Rini, Brian I.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Smoragiewicz, Martin
    Alva, Ajjai Shivaram
    Srinivas, Sandy
    Wood, Lori
    Brugarolas, James
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Broom, Reuben James
    Kanesvaran, Ravindran
    Bamias, Aristotelis
    Knox, Jennifer J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy
    Petrioli, Roberto
    Paolelli, Loretta
    Francini, Edoardo
    Marsili, Stefania
    Pascucci, Alessandra
    Sciandivasci, Angela
    de Rubertis, Giovanni
    Barbanti, Gabriele
    Manganelli, Antonio
    Salvestrini, Francesco
    Francini, Guido
    ANTI-CANCER DRUGS, 2007, 18 (07) : 817 - 820
  • [25] The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma
    Lan, Chi-Chen
    Chiu, Tai-Jan
    Hung, Chia-Yen
    Yeh, Kun-Yun
    Lu, Chang-Hsien
    Chen, Yen-Yang
    Chen, Jen-Shi
    Hung, Yu-Shin
    Chou, Wen-Chi
    PANCREATOLOGY, 2025, 25 (02) : 266 - 274
  • [26] Pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma
    Zhang, Bin
    Li, Rui
    Chang, Chun-Xiao
    Han, Yong
    Shi, Sheng-Bin
    Tian, Jing
    ONCOTARGETS AND THERAPY, 2016, 9 : 3901 - 3906
  • [27] Recent developments in second and third line therapy of metastatic renal cell carcinoma
    Vitale, Maria Giuseppa
    Carteni, Giacomo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (05) : 469 - 471
  • [28] Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
    Gaulin, J.
    Kotb, R.
    Turcotte, E.
    Berard, G.
    Sawan, B.
    Schmutz, G.
    Beauregard, P.
    CURRENT ONCOLOGY, 2009, 16 (05) : 331 - 333
  • [29] Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
    Paolo Grassi
    Elena Verzoni
    Raffaele Ratta
    Luca Porcu
    Michele Prisciandaro
    Alessia Mennitto
    Giuseppina Calareso
    Filippo de Braud
    Giuseppe Procopio
    Drugs in R&D, 2017, 17 : 461 - 467
  • [30] Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?
    Fuca, G.
    Verzoni, E.
    Ratta, R.
    Luca, P.
    Martinetti, A.
    Mennitto, A.
    Grassi, P.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2017, 28
12345